当前位置: X-MOL 学术Nat. Med. › 论文详情
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Nature Medicine ( IF 30.641 ) Pub Date : 2020-01-13 , DOI: 10.1038/s41591-019-0716-8
Alexander Drilon; Jeffrey W. Clark; Jared Weiss; Sai-Hong Ignatius Ou; D. Ross Camidge; Benjamin J. Solomon; Gregory A. Otterson; Liza C. Villaruz; Gregory J. Riely; Rebecca S. Heist; Mark M. Awad; Geoffrey I. Shapiro; Miyako Satouchi; Toyoaki Hida; Hidetoshi Hayashi; Danielle A. Murphy; Sherry C. Wang; Sherry Li; Tiziana Usari; Keith D. Wilner; Paul K. Paik

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a multikinase inhibitor with potent activity against MET3. The antitumor activity and safety of crizotinib were assessed in 69 patients with advanced NSCLCs harboring MET exon 14 alterations. Objective response rate was 32% (95% confidence interval (CI), 21–45) among 65 response-evaluable patients. Objective responses were observed independent of the molecular heterogeneity that characterizes these cancers and did not vary by splice-site region and mutation type of the MET exon 14 alteration, concurrent increased MET copy number or the detection of a MET exon 14 alteration in circulating tumor DNA. The median duration of response was 9.1 months (95% CI, 6.4–12.7). The median progression-free survival was 7.3 months (95% CI, 5.4–9.1). MET exon 14 alteration defines a molecular subgroup of NSCLCs for which MET inhibition with crizotinib is active. These results address an unmet need for targeted therapy in people with lung cancers with MET exon 14 alterations and adds to an expanding list of genomically driven therapies for oncogenic subsets of NSCLC.
更新日期:2020-01-14

 

全部期刊列表>>
2020新春特辑
限时免费阅读临床医学内容
ACS材料视界
科学报告最新纳米科学与技术研究
清华大学化学系段昊泓
自然科研论文编辑服务
中国科学院大学楚甲祥
中国科学院微生物研究所潘国辉
中国科学院化学研究所
课题组网站
X-MOL
北京大学分子工程苏南研究院
华东师范大学分子机器及功能材料
中山大学化学工程与技术学院
试剂库存
天合科研
down
wechat
bug